Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul;9(13):4632-4639.
doi: 10.1002/cam4.3099. Epub 2020 May 7.

High incidence of RAS pathway mutations among sentinel genetic lesions of Korean pediatric BCR-ABL1-like acute lymphoblastic leukemia

Affiliations

High incidence of RAS pathway mutations among sentinel genetic lesions of Korean pediatric BCR-ABL1-like acute lymphoblastic leukemia

Jae Wook Lee et al. Cancer Med. 2020 Jul.

Abstract

Introduction: Recent advances in genetic analysis have led to the discovery of novel genetic subtypes of precursor B-cell acute lymphoblastic leukemia (B-ALL) with prognostic relevance. In this study, we studied a cohort of pediatric B-ALL patients to retrospectively determine the incidence of patients harboring novel genetic subtypes, as well as their outcome.

Methods: B-ALL patients (N = 190) diagnosed in a single Korean hospital were included in the study. Patients' medical records were reviewed for data on established genetic abnormalities and outcome. CRLF2 expression was analyzed by quantitative RT-PCR. Anchored multiplex PCR-based enrichment was used to detect fusions and point mutations in 81 ALL-related genes.

Results: Incidence of established recurrent genetic subtypes was as follows: high hyperdiploidy (21.6%), ETV6-RUNX1 (21.6%), BCR-ABL1 (7.9%), KMT2A rearrangement (7.4%) TCF3-PBX1/TCF3-HLF (7.4%), and hypodiploidy (1.1%). Incidence of new genetic subtypes was as follows: BCR-ABL1-like (13.2%), ETV6-RUNX1-like (2.1%), EWSR1-ZNF384 (1.1%), and iAMP21 (1.1%). Median age at diagnosis of BCR-ABL1-like ALL was 6.8 years. According to type of genetic abnormality, BCR-ABL1-like ALL was divided into ABL class (12%), CRLF2 class (8%), JAK-STAT class (12%), and RAS class (68%). The 5-year event-free survival (EFS) of BCR-ABL1-like patients was significantly inferior to non-BCR-ABL1-like low- and standard-risk patients (71.5 ± 9.1% vs 92.5 ± 3.2%, P = .001) and comparable to non-BCR-ABL1-like high (75.2 ± 6.2%) and very high-risk patients (56.8 ± 7.4%). All four ETV6-RUNX1-like patients survived event-free.

Conclusion: Analogous to previous studies, incidence of BCR-ABL1-like ALL in our cohort was 13.2% with outcome comparable to high and very high-risk patients. A significantly high number of RAS class mutations was a distinct feature of our BCR-ABL1-like ALL group.

Keywords: BCR-ABL1-like; RAS mutation; acute lymphoblastic leukemia.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

FIGURE 1
FIGURE 1
Genetic and clinical characteristics of patients. Data are shown for 25 patients with BCR‐ABL1‐like ALL, 4 with ETV6‐RUNX1‐like ALL and 13 other B‐ALL. ABL1r, ABL1 rearrangement; FLT3r, FLT3 rearrangement; NCI, National Cancer Institute/Rome
FIGURE 2
FIGURE 2
Comparison of 5‐y EFS of BCR‐ABL1‐like ALL subgroup and non‐BCR‐ABL1‐like low and standard risk subgroup (A), and non‐BCR‐ABL1‐like high risk subgroup (B)

Similar articles

Cited by

References

    1. Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009;360(5):470‐480. - PMC - PubMed
    1. Den Boer ML, van Slegtenhorst M, De Menezes RX, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome‐wide classification study. Lancet Oncol. 2009;10(2):125‐134. - PMC - PubMed
    1. Harvey RC, Mullighan CG, Wang X, et al. Identification of novel cluster groups in pediatric high‐risk B‐precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome‐wide DNA copy number alterations, clinical characteristics, and outcome. Blood. 2010;116(23):4874‐4884. - PMC - PubMed
    1. Roberts KG, Li Y, Payne‐Turner D, et al. Targetable kinase‐activating lesions in Ph‐like acute lymphoblastic leukemia. N Engl J Med. 2014;371(11):1005‐1015. - PMC - PubMed
    1. Reshmi SC, Harvey RC, Roberts KG, et al. Targetable kinase gene fusions in high‐risk B‐ALL: a study from the Children's Oncology Group. Blood. 2017;129(25):3352‐3361. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources